Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit Review(R)-(+)-8-Hydroxy-DPAT hydrobromide is a full 5-HT1A serotonin receptor agonist. Reduces hippocampal 5-HT levels following systemic administration in rats in vivo. More active enantiomer of 8-Hydroxy-DPAT hydrobromide.
Racemate and 7-Hydroxy Isomer also available.
M. Wt | 328.29 |
Formula | C16H25NO.HBr |
Storage | Desiccate at +4°C |
Purity | ≥98% (HPLC) |
CAS Number | 78095-19-9 |
PubChem ID | 11957570 |
InChI Key | BATPBOZTBNNDLN-PFEQFJNWSA-N |
Smiles | Br.CCCN(CCC)[C@@H]1CCC2=CC=CC(O)=C2C1 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
References are publications that support the biological activity of the product.
Bjork et al (1989) Resolved N,N-dialkylated 2-amino-8-hydroxytetralins: stereoselective interactions with 5-HT1A receptors in the brain. J.Med.Chem. 32 779 PMID: 2522991
Corrfield et al (1991) Intrinsic activity of enantiomers of 8-hydroxy-2-(di-n-propylamino)tetralin and its analogues at 5-hydroxytryptamine1A receptors that are negatively coupled to adenylate cyclase. Mol.Pharmacol. 39 780 PMID: 1828859
Yoshitake and Kehr (2004) Differential effects of (R)-, (R, S)- and (S)-8-hydroxy-2-(di-n-propylamino)tetralin on hippocampal serotonin release and induction of hypothermia in awake rats. Life Sci. 74 2865 PMID: 15050424
Keywords: (R)-(+)-8-Hydroxy-DPAT hydrobromide, (R)-(+)-8-Hydroxy-DPAT hydrobromide supplier, Selective, 5-HT1A, agonists, active, enantiomer, Serotonin, Receptors, 1080, Tocris Bioscience
Citations are publications that use Tocris products. Selected citations for (R)-(+)-8-Hydroxy-DPAT hydrobromide include:
Sadiq et al (2019) 5-HT1A Receptor Function Makes Wound Healing a Happier Process. Front Pharmacol 9 1406 PMID: 30618734
Rossi et al (2008) Differential regulation of serotonin-1A receptor-stimulated [35S]GTP gamma S binding in the dorsal raphe nucleus by cital. and escital. Eur J Pharmacol 583 103 PMID: 18289523
Wierońska et al (2015) The antipsychotic-like effects in rodents of the positive allosteric modulator Lu AF21934 involve 5-HT1A receptor signaling: mechanistic studies. Oncoscience 232 259 PMID: 25012236
Cassilly et al (2016) SB-224289 Antagonizes the Antifungal Mechanism of the Marine Depsipeptide Papuamide A. Psychopharmacology (Berl) 11 e0154932 PMID: 27183222
Average Rating: 5 (Based on 1 Review.)
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Filter by:
Biologically active compounds that have been documented to interact with awide range of targets including SB-224289 (Cat. # 1221), MG-624 (Cat.# 1356), GVIA (Cat. No. 1085), DPAT hydrobromide (Cat. No. 1080) and valinomycin (VA; Cat. # 3373) were ordered from Tocris Bioscience
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Written by Nicholas M. Barnes and John F. Neumaier, this review summarizes the various serotonin receptor subtypes and their importance in mediating the role of serotonin in numerous physiological and pharmacological processes. Compounds available from Tocris are listed.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.